| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-08-30 | Stada (Germany) Richter (Hungary) | biosimilar products for monoclonal antibody rituximab | licensing |
Cancer - Oncology - Autoimmune diseases | Licensing agreement | |
| 2011-08-30 | Stada (Germany) Richter (Hungary) | biosimilar products for monoclonal antibody trastuzumab | licensing |
Cancer - Oncology | Licensing agreement | |
| 2011-08-30 | Ipsen (France) Inspiration Biopharmaceuticals (USA) | Inspiration's hemophilia portfolio | hemophilia | commercialisation |
Hematological diseases - Genetic diseases - Rare diseases | Commercialisation agreement |
| 2011-08-30 | Gedeon Richter (Hungary) Stada (Germany) | biosimilar rituximab - biosimilar version of Mabthera®/Rituxan® , biosimilar trastuzumab - biosimilar version of Herceptin® | licensing development commercialisation |
Cancer - Oncology - Autoimmune diseases | Licensing agreement | |
| 2011-08-29 | NovAliX (France) Galapagos (Belgium) | small molecule lead candidates | osteoarthritis | research - R&D | Rheumatic diseases - Inflammatory diseases – Bone diseases | R&D agreement |
| 2011-08-26 | Batavia Bioservices (The Netherlands) Xendo (The Netherlands) | bioprocess activities clinical support services development and analytical services | collaboration |
Collaboration agreement | ||
| 2011-08-22 | Isconova (Sweden) Genocea (USA) | Isconova’s adjuvant Matrix M™ | malaria gonorrhoea | licensing |
Infectious diseases | Licensing agreement |
| 2011-08-18 | Galapagos (Belgium) Genentech a member of the Roche Group (USA-Switzerland) | drug discovery programs | undisclosed | research - R&D | R&D agreement | |
| 2011-08-16 | Qiagen (Germany) Pfizer (USA - NY) | companion molecular diagnostic test for dacomitinib | non small cell lung cancer | research - R&D | Diagnostic - Cancer - Oncology | R&D agreement |
| 2011-08-16 | 4-Antibody AG (Switzerland) Human Genome Sciences (USA) | fully human therapeutic antibodies | collaboration |
R&D agreement | ||
| 2011-08-12 | Lonza (Switzerland) ImmuneMed (South Korea) | services | Infectious diseases | |||
| 2011-08-11 | co.don AG (Germany) Asklepios Group (Germany) | cartilage cell transplants | regenerative treatment of damaged cartilage | Manufacturing Production Collaboration |
Rheumatic diseases - Bone diseases | |
| 2011-08-11 | Evotec (Germany) undisclosed tier animal health company | EVT401 | licensing collaboration |
Veterinary diseases | Licensing agreement | |
| 2011-08-10 | Boehringer Ingelheim (Germany) Probiogen (Germany) | GlymaxX® Antibody Glyco-Engineering technology | licensing |
Licensing agreement | ||
| 2011-08-10 | GSK (UK) Enigma Diagnostics (UK) | Enigma® ML system | Supply |
Respiratory diseases | Commercialisation agreement | |
| 2011-08-09 | Servier (France) Intercept Pharmaceuticals (USA) | novel TGR5 agonists | type 2 diabetes and other metabolic indications | research - R&D | Metabolic diseases | R&D agreement |
| 2011-08-02 | SuppreMol (Germany) Protagen (Germany) | biomarkers | systemic lupus erythematosus | research - R&D | Autoimmune diseases | R&D agreement |
| 2011-08-01 | SkyePharma (UK) Aenova (Germany) | manufacturing - production | Production agreement | |||
| 2011-08-01 | Merck&Co (USA) Morphosys (Germany) | HuCAL GOLD technology | licensing |
Licensing agreement | ||
| 2011-07-27 | Bayer (Germany) Trius Therapeutics (USA) | torezolid | acute bacterial skin and skin structure infections | development |
Infectious diseases | Development agreement |
